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Abstract
Neuroendocrine neoplasms/tumours (NENs/NETs) of the large intestine are detected increasingly often, especially rectal tumours, which 
is probably associated with the widespread use of screening colonoscopy.
There is a growing body of evidence supporting the thesis that the NENs of the rectum and the NENs of the colon are two different 
diseases. Rectal NENs are usually small lesions, of low to moderate histological malignancy, associated with good prognosis, and most 
may be treated endoscopically. NENs of the colon, however, are often aggressive, poorly differentiated, associated with a poor or uncer-
tain prognosis, and require surgical treatment. The management guidelines regarding these groups of patients are constantly changing. 
On the basis of the recent literature data and conclusions reached by the working meeting of the Polish Network of Neuroendocrine 
Tumours (December 2016), this study completes and updates the data and management guidelines regarding colorectal NENs published 
in Endokrynologia Polska 2013; 64: 358–368.
(Endokrynol Pol 2017; 68 (2): 250–260)
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1. Epidemiology
1.1. Introduction
The rate of detection of colorectal neuroendocrine neo-
plasms (NENs) is increasing, and this tendency is likely 
to continue due to the widespread use of colonoscopy, 
including as a screening tool, and the removal of all di-
agnosed lesions [1–9]. The authors of the recent ENETS 
consensus state that there is a growing body of evidence 
supporting the thesis that the NEN of the rectum and 
the NEN of the colon are two different diseases [9].
1.2. Epidemiology
Rectal NENs are usually small lesions (most < 1 cm), and 
their histological malignancy is low to moderate (G1, G2), 
whereas NENs of the colon are often aggressive, poorly 
differentiated, and more malignant (G3). Colonic NENs 
account for 7.8% and rectal NENs for 13.7% of all neu-
roendocrine neoplasms [2]. The most common site for 
colonic tumours is the caecum, and this location is more 
frequent in females [2]. The mean age at disease onset is 
70 years [3]. Rectal tumours are the third largest group of 
gastrointestinal NENs. They account for approximately 
1% of all rectal tumours. They are detected by one in 
1000–2000 endoscopic examinations [1, 5, 6, 10]. Since 
the year 2000, rectal NENs occur or are detected more 
frequently than small intestinal NENs [9]. This is pro-
bably associated with the widespread use of screening 
colonoscopy [1, 8, 9]. According to Japanese and Korean 
data, rectal NENs are slightly more common in the male 
population (M/F ratio — 1.5 and OR 1.9) [11], whereas 
American and Polish data demonstrate a similar preva-
lence of these neoplasms in both sexes [2, 5, 9]. In the 
USA, the highest incidence of these neoplasms is found 
in Asian (OR = 10) and black patients (OR = 1.96) [8, 11].
The mean age of patients with rectal NENs is 56 
years. The statistical data records 4.2 cases of rectal 
NENs per 1,000,000 citizens [8, 11].
Rectal NENs are typically single lesions, although 
multiple lesions have also been described in the lit-
erature. Complete colonoscopy is recommended if 
neuroendocrine lesions are found in the rectum [12].
2. Clinical characteristics
2.1. Clinical characteristics and symptomatology
Colorectal neuroendocrine neoplasms arise from two 
types of cell:
 — EC (enterochromaffin) cells, which secrete seroto-
nin, and are typically located in the ascending colon;
 — L cells, which secrete glucagon-like peptide (GLP) 
and YY peptide, and are found in the remaining 
part of the colon and rectum [8].
Colorectal NENs characteristically do not secrete 
specific hormones, and their clinical symptoms correlate 
with their location and stage of advancement [8].
The symptoms associated with colonic neuroendo-
crine neoplasms are non-specific. They mainly include 
changes in bowel movements (mostly diarrhoea) and, 
in the case of advanced disease, abdominal pain, weight 
loss, and palpable lesions in the abdominal cavity. 
Weakness and decreased effort tolerance, often associ-
ated with gastrointestinal blood loss, may also occur. 
Moreover, patients may suffer from gastrointestinal 
obstruction, which often requires an urgent surgical 
intervention. The above symptoms are similar for all 
neoplasms occurring in this part of the gastrointestinal 
tract, suggesting the initial diagnosis of adenocarci-
noma, the most common neoplasm affecting the large 
intestine. Despite the presence of serotonin-producing 
cells, carcinoid syndrome with its characteristic symp-
toms is rarely observed (< 5%) [3]. According to the 
largest database, SEER, the local lesions account for 
approximately 45% at the moment of diagnosis [13]. 
Distant metastases are found in 16–40% of patients. The 
five-year survival rate in colonic tumours, the lowest 
of all the gastrointestinal neuroendocrine neoplasms, is 
40–70%, depending on the size of the primary tumour, 
histological grade, and clinical stage [2, 13]. The mean 
survival time is 261 months for locally advanced lesions, 
and less in the case of regional lymph node metastases 
or distant metastases (36 months and 5 months, respec-
tively) [8, 13].
Rectal neuroendocrine neoplasms are most fre-
quently detected accidentally during an endoscopic 
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examination. The symptoms are also non-specific, 
including changes in bowel movement, gastroin-
testinal bleeding, or tenesmus. Carcinoid syndrome 
almost never occurs, due to the very rare presence 
of EC serotonin-secreting cells in this location (0.1%). 
At the moment of diagnosis, the majority (75–85%) of 
detected lesions are localised. The five-year survival 
rate is 75–100%, depending on the histological grade, 
proliferation index, and clinical stage [2].
Multiple Endocrine Neoplasia (MEN) syndrome 
and other genetically conditioned syndromes are very 
rarely associated with colorectal NENs [7, 8]. NENs in 
first-line family members increase the risk of the disease 
by a factor of four.
In 13% of patients with a colorectal NEN, another 
neoplasm develops [2, 4, 5]. The gastrointestinal tract, 
including the colon, is the most common site for syn-
chronous tumours, while metachronous neoplasms 
primarily affect the lungs, prostate gland, and urinary 
tract. The detection of gastric GIST as a metachronous 
tumour in a patient with rectal NEN has been presented 
by Polish authors [14].
3. Diagnostics
3.1. Biochemical diagnostics
There is no specific marker for colorectal neuroendo-
crine neoplasms. Determination of serum chromogra-
nin A concentration is still the most valuable method of 
monitoring, treating, and anticipating the course of the 
disease. CgA concentration may be elevated and cor-
relate with the severity of the neoplastic disease [15, 16] 
(*evidence level 3).
As tumours in this part of the gastrointestinal tract 
rarely secrete serotonin, the concentration of 5-hydrox-
yindoleacetic acid in the 24-hour urine collection usu-
ally remains normal. The concentration of serum acid 
phosphatase may be elevated in the case of neoplasms 
demonstrating expression of the prostate-specific frac-
tion [8, 17, 18] (* evidence level 5).
Minimal consensus statement on biochemical tests:
— serum CgA remains the most important biochemical 
marker in the diagnostics, monitoring, and establishing the 
prognosis in colorectal NENs.
3.2. Pathomorphological diagnostics
3.2.1. Pathogenesis
Similarly to the above discussed NENs in different 
gastrointestinal locations, colorectal neuroendocrine 
neoplasms are divided into well-differentiated neu-
roendocrine neoplasms with Ki-67 below 3% — NET 
G1, with Ki-67 index between 3 and 20% — NET G2, 
and with Ki-67 over 20% – neuroendocrine carcinomas 
(NECs): large- or small-cell, as well as mixed neuroendo-
crine non-neuroendocrine neoplasms (MINENs). There 
is also a small group of well-differentiated tumours with 
Ki-67 index over 20%, which in the AJCC eighth edi-
tion 2017 are referred to as NET G3 [19]. The diagnostic 
criteria are discussed in Chapter 2.2 and (Table V, VI and 
VII) (see p. 82–86).
Colonic neuroendocrine neoplasms are potentially 
malignant neoplasms. At the early stage they create 
polyps, which macroscopically resemble adenomas. 
However, at the moment of diagnosis they are usually 
exophytic tumours, which in the microscopic assess-
ment are diagnosed as neuroendocrine carcinomas 
or mixed neoplasms (MINENs). Most colonic NENs 
are highly malignant, and at diagnosis approximately 
30% of cases present metastases to the lymph nodes, 
mesentery, peritoneum, and liver [8].
Rectal neuroendocrine neoplasms are a different 
group; they are usually polyps, 1 to 2 cm in diameter, 
with the morphology of well-differentiated neoplasms 
(NET G1, NET G2), infiltrating the mucosa and/or sub-
mucosa, whereas neuroendocrine cancers (NECs) of 
the rectum demonstrate an aggressive clinical course. 
At the moment of diagnosis, metastases to the lymph 
nodes are often found. Colorectal neuroendocrine car-
cinomas are highly malignant neoplasms. Carcinomas 
arising from the large cells account for approximately 
75% of all colorectal NECs, and they are more frequently 
located in the right part of the colon. Sometimes they 
are associated with adenomas and adenocarcinomas. 
Their mitotic activity is high (median of 34/10 HPF), 
with a proliferative activity of more than 20%. Im-
munohistochemical examination sometimes indicates 
low chromogranin A expression and high expression 
of synaptophysin and CD 56. Small-cell carcinomas ac-
count for 25% of colorectal neuroendocrine carcinomas, 
and they are usually found in the distal section of the 
colon and rectum. They may be associated with squa-
mous cell carcinoma or classic adenocarcinoma. They 
demonstrate the expression of chromogranin A and 
synaptophysin; some tumours are cdx2-positive and 
TTF1-positive. The Ki-67 proliferation index is above 
50%, usually close to 100%. It should be emphasised that 
rectal NENs in 28 to 82% of cases express prostatic acid 
phosphatase, potentially resulting in a misdiagnosis of 
tumours arising in male patients [8]. Table I presents the 
pathogenesis of NENs of the colon and rectum
3.2.2. Diagnostic algorithm
In macroscopic assessment the following elements are 
considered:
 — Length of that part of the intestine obtained for 
examination, with the description of the tumour 
*evidence level according to OCEBM [68]
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location relative to the intestine resection margins 
(proximal, distal, and circumferential or radial mar-
gin, examined in the segments of the large intestine 
either unencased or incompletely encased by serosa, 
should be marked with ink);
 — Tumour assessment: number, size in three dimen-
sions, mutual relation of the tumours, cross-section 
appearance, considering extravasation and foci 
of necrosis, and the relation of the tumour to the 
intestinal wall layers;
 — Condition of the mucosa at the tumour site (ulcera-
tion present/not present);
 — Condition of the serosa at the tumour site;
 — Presence and size of the lymph nodes;
 — Presence of other tumours in the intestinal wall [8].
Microscopic assessment is based on the assessment 
of the following parameters:
1. Histological type of the NEN according to the WHO 
2017 classification [20], supplemented by Chapter 
2.2 and Tables V and VI (p. 82–86).
2. Histological grade G according to ENETS/WHO 
2017.
3. Pathomorphological pTNM staging according to 
ENETS and AJCC/UICC [19, 21]
4. Assessment of immunohistochemical expression 
of neuroendocrine markers: chromogranin A and 
synaptophysin, as well the Ki-67/MIB1 proliferative 
activity (obligatory).
5. Immunohistochemical assessment of the markers: 
NSE, CD56, CDX2, and serotonin (conditional).
6. Assessment of surgical margins.
Regarding 1 and 2: histopathological WHO 2017 
NEN classification and histological grading according to 
ENETS/WHO 2017 are presented in part one: "General 
guidelines for the management of gastro-entero-pan-
creatic neuroendocrine neoplasms (recommended by 
the Polish Network of Neuroendocrine Tumours)" (see 
p. 79–110).
Regarding 3: pathological and clinical pTNM staging.
The staging of colorectal neuroendocrine neoplasms is 
verified using the TNM classification according to AJCC/ 
/UICC and ENETS. As for the location of this neoplasm, 
both classifications are consistent. It is important, how-
ever, that the European Neuroendocrine Tumour Society 
classification is also applied to neuroendocrine carcino-
mas. According to the AJCC/UICC classification, NECs 
are assessed by the same criteria as adenocarcinomas, 
not as neuroendocrine neoplasms. Table II gives the TNM 
classification according to the AJCC and ENETS criteria. 
Table III gives the assessment criteria for clinical staging 
of colorectal NENs.
3.2.3. Prognostic indicators in the histopathological 
report
The risk factors of colorectal NEN associated with 
metastases, include: tumour > 2 cm in diameter, in-
vasion of the muscular layer of the colorectal wall, 
Table I. The pathogenesis of colorectal NENs 
Enterochromaffin 
cell (EC)
EC cell NENs are neuroendocrine neoplasms of the 
midgut (midgut-type NEN), which:
— occur mainly in the right part of the colon
— produce serotonin
— present histological and cytochemical 
characteristics similar to NENs in the 
ileocaecal area
— form, morphologically, solid nests surrounded by 
a circumferential palisade of cells, sometimes 
with rosette or bulbous structures, very rarely 
solid fields
— often have desmoplastic stroma
— have a differentiation grade of G1 or G2
— have tumour diameter of approximately 4.9 cm
— have positive cdx2 immunoexpression
L cell L cell NENs are neoplasms of the hindgut 
(hindgut-type NEN), which:
— are found in the distal section of the colon and 
rectum
— produce glucagon-like peptides (GLP-1), PP/
PYY, serotonin (30%), and somatostatin (20%)
— usually form submucosal, single polyp-like 
nodules covered by the intestinal epithelium
— are smaller than 1 cm in over 50% of the tumours
— create trabecular structures in the microscopic 
image, rarely rosette or tubular structures
— do not demonstrate immunoexpression of cdx2
Table II. TNM AJCC 8, UICC 8 Edition 2017 classification of 
colorectal NENs [19, 21]
Feature T — 
primary tumour 
x
Comments
pTX Tumour has not been assessed
pT0 No evidence of a primary tumour
pT1
pT1a 
pT1b
Tumour invades the mucosa or submucosa, size  
≤ 2 cm
Tumour size < 1 cm.
Tumour size 1–2 cm
pT2 Tumour invades the muscularis propria or size  
> 2 cm and invades the mucosa or submucosa
pT3 Tumour penetrates the muscularis propria and 
invades the subserosal tissue, without invading the 
serosa
pT4 Tumour invades the peritoneum, other organs or 
adjacent structures
*evidence level according to OCEBM [68]
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vasoinvasion, and > 2 mitotic figures/10 HPF. It is 
recommended that any focal tumour necrosis is deter-
mined, which indicates a more aggressive tumour [8].
An important parameter in the histopathological 
report on a colorectal NEN is the assessment of the 
proximal, distal, and circumferential margin. The cir-
cumferential margin is assessed in segments of gastroin-
testinal tract either unencased or incompletely encased 
by serosa. It should be noted that it should be marked 
with ink during the macroscopic assessment of the 
surgical material. It is recommended that the distance is 
noted between the tumour foci with the deepest infiltra-
tions and the circumferential margin line. A margin of 
> 1 mm indicates complete resection, whereas a margin of 
≤ 1 mm is interpreted as incomplete [8].
Minimal consensus statement on pathomorphological 
examination:
Minimal histopathological report on colorectal NEN 
should include:
 — Histological type of the neoplasm according to WHO clas-
sification, considering the division into well-differentiated 
neuroendocrine neoplasms (NET G1 and NET G2) with 
Ki-67 index below 20%, and NET G3 and neuroendocrine 
carcinomas (NECs) with Ki-67 index above 20% or mixed 
neoplasms (MINENs);
 — Histological G grading referring to well-differentiated 
neoplasms (NET G1, NET G2, NET G3) and NECs;
 — pTNM histopathological staging according to ENETS and 
AJCC/UICC 8 (2017) classification systems;
 — Assessment of surgical margins.
The histopathological diagnosis of NEN must be confirmed 
by immunohistochemical tests assessing expression of the 
neuroendocrine markers: synaptophysin and chromogranin 
A, as well as Ki-67 proliferative activity using the MIB1 
antigen (*evidence level 3).
3.3. Location diagnostics
3.3.1. Endoscopic diagnostics
The basic diagnostic method in colorectal NENs is co-
lonoscopy with a biopsy for morphological assessment, 
supplemented by echoendoscopic examination (EUS). 
EUS is mainly performed in rectal lesions. In colonic 
tumours diagnosed as submucosal polyps/lesions, the 
colonoscopic assessment may be supplemented by USG 
mini-probe. The large intestine may also be examined 
using capsule endoscopy [8, 23].
Colonic NENs are most frequently lesions that 
macroscopically resemble cancer infiltration; diag-
nosed early, they take the form of submucosal polyps/
tumours. Most rectal NENs (80%) demonstrate char-
acteristic morphological features. They are nodular 
with a wide base, smooth on the surface, covered by 
a mucosa of normal appearance or slightly yellow/
white [5–8]. Atypical features, observed in 20% of cases, 
include: semi-pedunculated shape, reddening of the 
mucosa, central depression, and erosion or ulceration 
on the surface. Atypical features occur mostly in lesions 
> 1 cm. Ulceration of the surface is associated with 
a worse prognosis. Lesions are usually single, and lo-
cated in the middle part of the rectum.
Contrary to other subepithelial lesions, in most pa-
tients (83%) with NEN, the biopsy results are positive [4]. 
This is because NENs arise from the muscular layer of 
the mucosa.
EUS allows the distinguishing of an epithelial polyp 
from a NEN (different echogenicity of lesions and dif-
ferent layer from which the lesion derives), determines 
the stage of local advancement, and helps in the choice 
of optimal therapy (i.e. endoscopic or surgical treat-
ment) [8, 9, 24]. Using EUS enables precise assessment 
of the size of the lesion, and determination of the depth 
of infiltration, and description of the condition of lymph 
nodes. The sensitivity and specificity of this test in the 
assessment of the depth of infiltration is 87% and 93%, 
respectively [6]. In EUS, colorectal NENs manifested 
as polyps are well demarcated, iso- or hypoechogenic, 
homogenous lesions derived from the muscular layer 
of the mucosa. The lesion may infiltrate the submucosa; 
deeper layers are invaded less frequently.
In the case of neuroendocrine rectal lesions of < 1 cm 
diameter, some authors do not recommend EUS as a tool 
for the assessment of the stage of disease advancement [24]. 
However, the recent ENETS guidelines strongly recom-
mend EUS in rectal NENs over 5 mm in diameter [9].
3.3.2. Other imaging examinations
As mentioned above, colonoscopy supplemented 
by EUS examination is essential in the diagnostics of 
colorectal tumours. In the case of lesions closing the 
intestinal lumen, full colonoscopy is impossible. In 
such cases, recommended are multiphase abdominal 
and pelvic CT (computed tomography)/MRI (magnetic 
resonance imaging), before and after the administration 
of the contrast medium, after filling the gastrointestinal 
tract with negative contrast, or CT colonography [8, 26].
Table III. Colorectal GEP NENs staging according to TNM 
AJCC 8, UICC. Edition 2017 [19, 20]
Stage I T1 N0 M0
Stage IIa T2 N0 M0
Stage IIb T3 N0 M0
Stage IIIa T4 N0 M0
Stage IIIb Any T N1 M0
Stage IV Any T, any N M1
*evidence level according to OCEBM [68]
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To assess the stage of advancement, abdominal 
ultrasonography (US), CT/MRI, and somatostatin recep-
tor imaging (SRI) may be used. Abdominal ultrasound 
is a useful tool for the initial assessment of hepatic 
metastases and for planning/performing a biopsy. To 
assess the lesions in the chest, abdominal cavity, and 
pelvis multiphase computed tomography or magnetic 
resonance (abdominal cavity and pelvis) is used. MRI 
of the pelvis is the method of choice to assess the local 
advancement of a rectal neoplasm. There are no sepa-
rate data available for the sensitivity of SRI in the group 
of patients with colorectal NETs. SRI enables detection 
of lesions with increased somatostatin receptor (SSTR) 
expression, which is necessary to determine patient 
eligibility for treatment with somatostatin analogues 
or for radioisotope therapy based on these receptors 
(peptide receptor radionuclide therapy, PRRT) [8].
In the case of negative SRI results, a PET/CT exami-
nation should be considered after the administration of 
18F DOPA, for NECs and for quickly growing NENs, and 
PET/CT scan after the administration of 18FDG [27, 28].
Minimal consensus on imaging examinations:
 — Colonoscopy is the test of choice in the diagnostics of 
colorectal tumours.
 — EUS is recommended in rectal NENs ≥ 5 mm.
 — CT/MRI/SRI is recommended for assessing the stage of 
tumour advancement and detecting metastases (*evidence 
level 2/3).
 — SRI is required to determine a patient’s eligibility for an-
tiproliferative treatment with SSA and PRRT (*evidence 
level 2/3).
 —  18FDG PET/CT examination is indicated in patients with 
NECs, with rapidly growing NETs, and in patients quali-
fied for radioisotope therapy (*evidence level 3).
4. Treatment
4.1. Surgical treatment
4.1.1. Surgical treatment of colonic NENs
Recommendations regarding surgical treatment of 
colonic NENs are analogous  to  those  regarding 
the treatment of colonic adenocarcinoma [8]. Resec-
tion (performed by open or laparoscopic access) with 
lymphadenectomy is indicated in patients with tu-
mours without distant metastases (*evidence level 1). In 
the case of  NENs G1 and G2 with distant metastases 
(usually to the liver), a palliative resection with regional 
lymphadenectomy is recommended (*evidence level 1) or, 
if possible, maximal cytoreduction of the tumour (*evi-
dence level 2), even if complete reduction is not achieved.
In the case of invasion of the adjacent organs, if 
possible from the technical point of view, a multi-
organ excision with left- or right-sided hemicolectomy 
is suggested, or extensive resections of the transverse 
colon, considering the extent of the lymphatic drainage 
(*evidence level 1) [8].
4.1.2. Surgical treatment of rectal NENs
If the lesion does not qualify for endoscopic treatment 
(ESD), surgical therapy is the method of choice. Clas-
sical surgical techniques include low anterior resection 
or abdominosacral/perineal amputation of the rectum, 
whereas minimally invasive methods include transanal 
endoscopic microsurgery (TEM) or laparoscopic resec-
tional procedures.
Figure 1 gives the r e c o m m e n d e d  algorithm for 
the treatment of rectal neuroendocrine neoplasms [8].
Indications for local resection of rectal NEN (TEM, 
ESD) include tumour size < 1 cm, absence of lymph 
node invasion, and good tumour differentiation [7]. 
Local treatment of larger lesions, up to 2 cm, is possible. 
The treatment is considered sufficient if the pathomor-
phological examination does not reveal any adverse 
prognostic factors [7–9].
Local excision using the TEM technique is a prom-
ising therapeutic option because it enables transanal 
transmural excision of the lesion. Literature data reveals 
the superiority of TEM over classical local excision 
through the open anus because the method demon-
strates high efficacy and safety in groups of carefully 
selected patients [29].
In a study by Kim et al. (2012), in 97% of patients 
undergoing the TEM procedure free margins were 
obtained in the histopathological examination [30].
In another study, Wu et al. demonstrated a higher 
rate of free margins obtained after using the TEM tech-
nique (100%) compared to ESD and EMR (82.6% and 
65.5%, respectively) [31].
Tumours > 2 cm in diameter (according to some au-
thors, even those > 1.5 cm) are frequently associated with 
infiltration of the muscle membrane. In such cases resec-
tional procedures are recommended, preferably saving 
the sphincters. Anterior resection of the rectum with 
total excision of the mesorectum (TME, total mesorectal 
excision) is the procedure of choice, possibly including 
construction of protective stomy [8, 32].
Radical resection is also recommended in the pres-
ence of other risk factors for the regional lymph nodes, 
such as: high tumour mitotic index (G2, G3, Ki-67 > 2%), 
invasion of lymphatic and blood vessels, or positive 
expression of HES77 [33, 34].
In the case of T3 and T4 tumours with invasion to 
the local lymph nodes, oncological radicality can be 
achieved, provided there are no distant metastases.
If the tumour is located low in the rectum, or if it in-
vades the sphincter, then abdominosacral or abdominop-
*evidence level according to OCEBM [68]
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erineal amputation are recommended (*evidence level 1). 
The most recent data also question the established limit 
diameter. Some authors suggest that tumour size over 
15 mm is the cut-off point between local excision and ab-
dominoperineal rectal amputation because in this group 
the risk of distant metastases is very high. In such cases 
ESD resection is burdened with a high risk of oncological 
failure. In special cases, especially if the patient does not 
consent to a radical procedure, using the TEM technique 
can be an optimal solution. However, the patient must be 
informed that in the case of unfavourable results of the 
histopathological examination of the tumour removed via 
TEM, a radical rectal resection may be necessary.
In a series of cases described by Gleeson et al., no 
metastases were found if the lesion size did not exceed 
9 mm [35]. Local resection was considered safe in lesions 
of 10 to 16 mm in diameter in the study by McDermott 
et al. (however, it was a collective analysis, in which the 
quality of data was evaluated as low or moderate for all 
the cases included in the series) [36]. One study questioned 
the superiority of a radical resection over a local excision 
procedure in the case of rectal NENs of 10 to 20 mm in di-
ameter, with or without lymph node invasion, because the 
radical resection may adversely affect quality of life [37].
In locally and systemically advanced tumours with 
distant metastases, radical resections are not recom-
mended because in this group of patients survival is 
6–9 months following the diagnosis [8, 9].
Palliative surgery is indicated in the case of a bleed-
ing tumour if local haemostasis is ineffective (e.g. argon 
plasma coagulator, APC), or gastrointestinal obstruction 
(*evidence level 1). In NETs of G1 and G2 with metastases 
limited to the liver a radical local excision of the tumour 
with subsequent resection of hepatic parenchyma (me-
tastasectomy) (*evidence level 1) or, in certain cases, a liver 
transplant (*evidence level 4) [8]. However, it should be 
emphasised that the available literature presents only 
the results of treatment of individual series of patients 
with colorectal NENs with hepatic metastases [38].
In the case of incomplete excision of a rectal tumour 
during an endoscopic procedure, it is recommended 
that salvage surgery is performed. Analysis of the lit-
erature does not allow the unambiguous establishment 
of whether salvage treatment is necessary, and if it is, 
the data does not indicate clearly which option is the 
best. Therefore, each case should be treated individu-
ally, based on the patient’s risk factors and the clinical 
experience of the physician and the centre. Following 
incomplete resection with endoscopic techniques or 
after procedures performed with other techniques, the 
patient should be referred to centres specialising in the 
treatment of NENs (Fig. 2).
Minimal consensus statement on surgical treatment:
 — Colonic NENs mostly require surgical treatment.
 — Rectal NENs associated with adverse prognostic factors 
(regardless of the size)
 — and tumours of 2 cm or more in diameter should be treated 
surgically.
4.2. Endoscopic treatment of colorectal 
neuroendocrine neoplasms
For endoscopic treatment of colorectal NENs, eligible 
patients should be those who are at almost no risk of 
metastases to regional lymph nodes or of distant me-
Treatment of rectal NENs
Any NEN < 1 cm 
or 1–2 cm
without adverse 
prognostic factors
Endoscopic/
/microsurgical
 treatment
Any > 2 cm 
or 1–2 cm 
with adverse
 prognostic factors
Surgical 
treatment
*Transanal Laparoscopic 
Through 
open access
ESD
TEM
Trough 
the open 
rectum access
Abdominoperineal 
amputation 
of the rectum
Anterior 
resection 
of the rectum
Abdominoperineal 
amputation 
of the rectum
TEM
Figure 1. Algorithm for the treatment of neuroendocrine rectal 
neoplasms (according to Starzyńska et al. [8]); *in individual cases
Figure 2. Algorithm of management in case of incomplete TEM 
or endoscopic treatment (according to Hyoung RK et al. [39])
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tastases. Endoscopic mucosal dissection (ESD) is the 
optimal treatment method because it is associated with 
the highest R0 resection rate [40–44].
In colonic NENs, due to the high risk of metastases 
to regional lymph nodes, surgical treatment is recom-
mended. In a study based on a large group of patients 
with colonic NENs treated surgically (923 patients), Al. 
Natour et al. analysed the relationship between the size 
of lesion, depth of invasion, and occurrence of metasta-
ses. The authors demonstrated that in the case of early 
detected lesions, smaller than 1 cm, and limited to the 
mucosa, the risk of metastases to the regional lymph 
nodes was 4%, and for other lesions it was ≥ 14% [45].
Approximately 80% of rectal NENs qualify for en-
doscopic local therapy. It has been documented that in 
rectal NENs the size of the tumour is a sensitive indica-
tor of the risk of the metastases to the regional lymph 
nodes and disease progression [36]. It has also been 
demonstrated that only in patients with neoplasms of < 
10 mm the risk of metastases is low and prognosis good. 
In this group, the ratio of patients with regional lymph 
node invasion is 3%, and with distant metastases it is 
1.6%. With tumours of 11–19 mm, the risk of metastases 
increased to 66%, and 50% for regional lymph nodes 
and distant metastases. In the case of lesions > 20 mm, 
in 73% of patients metastatic lesions were found in the 
lymph nodes at the diagnosis, while in all of the patients 
(100%) distant metastases occurred.
Established prognostic factors include depth of 
invasion, vascular status, and proliferation index. Bad 
prognostic markers/risk factors include invasion of 
the muscularis propria, lymph node invasion or/and 
angioinvasion, and proliferation index > 2%.
According to McDermott et al., rectal NENs of up 
to 10 mm, without any risk factors, are eligible for 
endoscopic treatment [37]. In the group of lesions 
10–20 mm in diameter the neoplasm may be removed 
endoscopically, and after assessment of the preparation/ 
/risk factors, further management can be determined. 
Rectal NENs > 20 mm, and those with bad prognostic 
markers, should undergo radical surgical treatment, 
including resection of the mesorectum.
Classical polypectomy cannot be performed in the 
treatment of colorectal neuroendocrine neoplasms be-
cause these lesions derive from the second layer of the 
gastrointestinal wall (muscularis mucosae) and grow 
towards the submucosa. In most cases, with small le-
sions (up to 1 cm), endoscopic mucosal resection (EMR) 
is conducted, in different versions, as well as endoscopic 
submucosal dissection (ESD) [40–44]. The latter has been 
proven to be the method of choice. ESD, in comparison 
to EMR, provides a higher ratio of en bloc and R0 resec-
tions (100% vs. 89% and 82–91% vs. 65–70%), while the 
frequency of complications is similar. Most complications 
(delayed bleeding, perforation) may be treated endo-
scopically. No fatal complications have been reported.
ESD enables removal of the tumour in one piece (en 
bloc), within the healthy tissue, regardless of the size of 
the lesion or the presence of fibrosis. Application of this 
method became possible after the Olympus Tokyo com-
pany introduced a special knife (insulation tip-IT knife), 
which reduced the risk of perforation due to a porcelain 
ball-shaped tip. The procedure starts by marking the 
borders of the lesion, allowing for a healthy tissue margin. 
Saline solution with diluted adrenalin and indigo carmine 
is injected into the submucosa to elevate it and increase 
its volume. When a small incision is made, the next steps 
include performing a round incision and dissection of 
the lesion within the submucosa. Endoscopic treatment 
is associated with very good longterm results [41].
ESD procedures are performed in Poland in the fol-
lowing centres Department General, Gastroenterologi-
cal and Gastrointestinal Neoplasms Surgery Teaching 
Hospital, Medical University of Lublin; Endotherapy 
Non-public Health Care Facility in Warsaw; Depart-
ment Gastroenterology, CMKP, Warsaw; Oncology 
Centre, Bydgoszcz; Department of Gastroenterology, 
Medical University in Białystok; and the Department 
of Gastroenterology, Pomeranian Medical University 
in Szczecin. The largest number of procedures were 
performed in Szczecin.
Minimal consensus statement on endoscopic treatment:
 — Endoscopic treatment of colorectal NENs concerns mostly 
lesions in the rectum.
 — ESD is the treatment of choice among endoscopic tech-
niques.
 — Rectal NENs of up to 1 cm in diameter is an optimal 
indication for endoscopic treatment.
 — Rectal NENs of 10–20 mm in diameter may be removed 
endoscopically (ESD), and after the assessment of the prepa-
ration/risk factors, further management can be determined.
4.3. Pharmacological treatment
4.3.1. Biotherapy
Somatostatin analogues (SSA)
Carcinoid syndrome is very rare in colorectal neu-
roendocrine tumours. In the case of a disseminated 
neoplastic process with the symptoms of excessive 
serotonin secretion, using somatostatin analogues is 
the treatment of choice (*evidence level 1) [46]. In non-
functional neuroendocrine neoplasms (NF-NENs), 
there is no conclusive evidence of the anti-neoplastic 
effectiveness of SSA, but their effectiveness may not 
be excluded, due to the results of the CLARINET and 
RADIANT-2 studies [47,48].
*evidence level according to OCEBM [68]
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Targeted therapy — m-TOR inhibitors (everolimus)
An analysis of the RADIANT-2 subgroups, including 
only those patients with advanced G1/G2 colorectal 
NENs, has demonstrated that, statistically, the progres-
sion-free survival of the patients who received everoli-
mus plus octreotide LAR (median PFS 29.9 months, 
n = 19) was significantly longer than in those patients 
receiving placebo plus octreotide LAR (median PFS 6.6 
months, n = 20). Using both drugs (everolimus + SSA) 
in combination may be justified in the case of G1/G2 
neoplasms, but further verification is required [48]. The 
CLARINET study did not demonstrate any clear advan-
tages of using lanreotide; however, the data regarding 
neuroendocrine neoplasms of the large intestine in this 
subgroup was too limited to draw any conclusions.
Everolimus is recommended in non-resectable, lo-
cally advanced and/or metastatic colorectal NENs (G1 
and G2) as a second-line therapy, if SSA treatment is 
ineffective, or as a third-line therapy, if SAA and/or in-
terferon alpha (INF-α) (currently unavailable in Poland) 
and PRRT therapy is unsuccessful [46, 49].
4.3.2. Chemotherapy
Chemotherapy is indicated primarily in the treatment 
of patients diagnosed with neuroendocrine carcinomas 
(NEC). In the case of poorly-differentiated NECs, stand-
ard management should involve chemotherapy using 
platin derivatives [46, 50, 51]. Detailed recommendations 
are presented in “Diagnostic and therapeutic guidelines 
for gastro-entero-pancreatic neuroendocrine neoplasms” 
(see p. 79–110). Second-line therapy in patients with 
NECs should be considered individually, exclusively in 
patients with good function (*evidence level 4).
Regimens based on oxiplatin (FOLFOX, XELOX), 
irinotecan (FOLFIRI, IP), or temozolomide are recom-
mended (*evidence level 4) [52–56].
Chemotherapy involving platin derivatives may be 
repeated in patients who demonstrate good response to 
first-line treatment that persists for over three months, 
and if no side effects of the therapy are observed.
In patients with NETs chemotherapy is not recom-
mended, except for NET G2 with Ki-67 > 15%, and ag-
gressive course (RECIST progression within 3-6 months), 
or without SSTR expression, if other therapeutic methods 
are unsuccessful, i.e. the disease progresses despite the 
treatment with everolimus (presently not refunded for this 
indication in Poland) or INF-α (presently unavailable in 
Poland) [45]. Chemotherapy is based on temozolomide and/ 
/or capecitabine and/or capecitabine with bevacizumab (beva-
cizumab is not refunded in this indication in Poland) [57, 58].
Patients with MINEN of the large intestine should be 
treated following the standards of the oncological man-
agement intended for classical colorectal carcinomas.
Minimal consensus for pharmacological treatment:
 — In patients with colorectal NETs with carcinoid syndrome 
symptoms, SSA therapy is a treatment of choice.
 — In patients with non-surgical, locally advanced, and/or 
metastatic colorectal NETs G1 and G2 without SSTR 
expression, SAA should be considered as the first-line an-
tiproliferative therapy; in case of progression, everolimus 
or PRRT is recommended.
 — In patients with Ki-67 > 15%, if the disease still pro-
gresses rapidly, temozolomide and/or capecitabine-based 
chemotherapy is recommended.
 — In patients with NECs, the treatment of choice involves 
chemotherapy with the use of platin derivatives.
4.4. Peptide Receptor Radionuclide Therapy with 
radioisotope-labelled somatostatin analogues 
(PRRT)
Presently, there is very limited data concerning the 
effectiveness of targeted therapy with radioisotope-
labelled somatostatin analogues in the group of pa-
tients with colorectal NENs. The observed survival 
following PRRT is shorter than in midgut tumours [59]. 
However, there are no randomised data in this group 
of patients. Qualification and treatment should follow 
the principles described in “Diagnostic and therapeutic 
guidelines for gastro-entero-pancreatic neuroendocrine 
neoplasms (recommended by the Polish Network of 
Neuroendocrine Tumours)” (see p. 79–110).
PRRT in hindgut tumours should be considered in 
patients with diffused or non-resectable NETs, demon-
strating high overexpression of somatostatin receptors, 
confirmed by SRI examination [59–68].
Minimal consensus statement on radioisotope treat-
ment:
PRRT should be considered in patients with diffused or 
non-resectable hindgut NETs, if the tumour presents high 
overexpression of somatostatin receptors in the SRI examina-
tion (*evidence level 3/4).
4.5. Follow-up 
After a complete endoscopic or surgical removal of the 
colorectal neuroendocrine neoplasm, the following 
follow-up is recommended [7, 8, 22]:
 — G1, G2 tumours up to 1 cm, without lymph node me-
tastases, without invasion of the muscularis propria – 
regular monitoring of patients is not recommended;
 — G3 tumours smaller than 1 cm and G1–3 tumours of 
1–2 cm: colonoscopy every 12 months;
 — tumours larger than 2 cm: obligatory follow-up ex-
aminations: G1/G2 tumours: colonoscopy/imaging 
examination/CgA in the first year; for G3 tumours, 
the same examinations every 4–6 months in the first 
year, then once a year.
*evidence level according to OCEBM [68]
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Follow-up imaging examinations:
 — for lesions in the rectum: EUS, colonoscopy, MRI;
 — for lesions in the colon: CT, colonoscopy;
 — liver assessment: contrast-enhanced MRI, multi-
detector CT.
It is recommended that serum CgA is determined 
for ten years.
A precise system of risk assessment for rectal NENs 
has been developed, including a combination of four 
features: size, depth of invasion, vascular invasion, and 
mitotic index [8, 21]. Each parameter can be awarded 
0–2 points (Table IV). Zero points means a low-risk 
patient, 1–2 points — a medium risk patient, and 3 or 
more points — a high-risk patient. Low-risk patients 
(lesion < 1 cm, limited to the mucosa/submucosa, 
without vascular invasion, mitotic index < 2/50 HPF) 
do not require imaging tests for the assessment of the 
stage of the disease, and do not need monitoring. In 
medium-risk patients imaging examinations should 
be considered and follow-up tests performed. High-
risk patients require imaging examinations before the 
planned treatment, and frequent follow-up examina-
tions, due to a high risk of distant metastases (47%) and 
local recurrence (31%).
Minimal consensus statement on follow-up:
Minimal consensus on follow-up examinations in colo-
rectal NENs:
 — for lesions in the rectum: EUS, colonoscopy, MRI;
 — for lesions in the colon: CT, colonoscopy;
 — liver assessment: contrast-enhanced MRI, multi-detector CT;
 — all lesions larger than 2 cm will require follow-up; smaller 
tumours should be followed up in the presence of poor 
prognostic factors (*evidence level 3).
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